ESSA Pharma

$2.98 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About ESSA Pharma

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

Stock Analysis

last close $2.98
1-mo return 20.2%
3-mo return -46.9%
avg daily vol. 421.54T
52-week high 14.88
52-week low 2.41
market cap. $131M
forward pe -
annual div. -
roe -20.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -

Subscribe now for daily local and international financial news